Characteristic features of ulcerative colitis with concomitant primary sclerosing cholangitis

Artur W. Uździcki, Marta Wawrzynowicz-Syczewska
Department of Infectious Diseases, Hepatology and Liver Transplantation, Pomeranian Medical University, Szczecin, Poland

Gastroenterology Rev 2021; 16 (3): 184–187
DOI: https://doi.org/10.5114/pg.2021.108983

Key words: ulcerative colitis, primary sclerosing cholangitis, inflammatory bowel disease.

Address for correspondence: Artur W. Uździcki, Department of Infectious Diseases, Hepatology and Liver Transplantation, Pomeranian Medical University, 4 Arkońska St, 71-455 Szczecin, Poland, e-mail: arturuzdzicki@gmail.com

Abstract

Ulcerative colitis is a chronic inflammatory bowel disease of the colon. The most frequent symptoms include bloody diarrhoea with rectal urgency and tenesmus, and the disease runs a relapsing – remitting course [8]. The peak age of disease onset is 30–40 years, and no sex predominance exists [9, 10]. Thirty-one percent of patients with UC limited at diagnosis will have disease extension by 10 years, and in 10–15% of patients the disease will lead to colectomy [11]. Younger age at onset (< 40 years), pancolitis, lack of endoscopic healing while in clinical remission, deep ulcerations, and high concentrations of perinuclear antineutrophil cytoplasmic antibodies have been identified as risk factors for aggressive or complicated disease [12]. UC can also cause extra-intestinal manifestations – both gastrointestinal (GI) and non-gastrointestinal. GI extra-intestinal manifestations of UC include primary sclerosing cholangitis, present in between 0.76% and 5.4% of UC patients, depending on the study [8]. In UC patients with higher incidence of acute or chronic pancreatitis, autoimmune hepatitis, primary biliary cholangitis, and atrophic gastritis have been described [8, 13]. Non-GI extra-intestinal manifestations most frequently occur in the musculoskeletal system, integument, ocular, and renal systems, respectively [8]. Rates of extra-intestinal manifestations are higher in children compared to adults [14]. Therapeutic agents, such as mesalamine, immunosuppressants, and biologic agents are used to induce and maintain remission [15].

Primary sclerosing cholangitis

Primary sclerosing cholangitis (PSC) is defined by the American Association for the Study of Liver Diseases (AASLD) as a chronic, cholestatic liver disease, characterised by the inflammation and fibrosis of both intrahepatic and extrahepatic bile ducts, leading to the formation of multifocal bile duct strictures [16]. It is a classic hepatobiliary manifestation of inflammatory bowel diseases,
such as ulcerative colitis [17]. The incidence varies geographically, and in northern Europe it is as high as 10 per 100,000 people per year, it is slightly more frequent in men, and the median age of onset is 30–40 years [17, 18]. Some studies suggest the increase in the incidence of PSC, which may partly result from the more frequent application of magnetic resonance cholangiography [19, 20].

The pathogenesis of PSC is unknown, but several groups of theories have been proposed, such as immune-targeted injury, toxic biliary damage, infectious triggers, and vascular insults. Gut microbiota disturbances and recruitment of gut-derived T cells to the liver have also been proposed as possible mechanisms [17, 21].

Most patients are asymptomatic at the time of the diagnosis, and only in 10–15% of patients are fever, night sweats, chills, pain in the right upper quadrant, itching, or jaundice present [22]. The most frequent signs at diagnosis are hepatomegaly (in 44% of patients) and splenomegaly (in 39% of patients) [23]. Sometimes, cholelithiasis, gallbladder carcinoma, pancreatitis, or colorectal cancer may be the first symptom of the disease [24]. Diagnostic criteria include exclusion of secondary sclerosing cholangitis and both laboratory (increase in serum alkaline phosphatase for more than 6 months) and imaging findings (bile duct strictures in either magnetic resonance imaging or endoscopic retrograde cholangiopancreatography) [25].

Primary sclerosing cholangitis is frequently associated with other diseases; the prevalence of ulcerative colitis in PSC patients differs widely in different countries – from 23% in Japan up to 80% in Sweden [26, 27]. The diagnosis of PSC may precede diagnosing the patient with IBD [21, 28]. Also, PSC may present even after colectomy in IBD patients [29]. In up to 25% other autoimmune diseases are present [30]. It is also a risk factor for colon, bile duct, and gallbladder cancers [31]. If primary sclerosing cholangitis is concomitant with inflammatory bowel disease, the risk of colon cancer is 10 times as high as in the general population, and 4 times higher than in patients with IBD alone [32].

Currently there is no effective medical therapy for primary sclerosing cholangitis, despite numerous clinical trials. Poor understanding of the pathogenesis of PSC makes it difficult to identify therapeutic agents [25]. Up to 40% of PSC patients will ultimately require liver transplantation, and PSC may recur in 25% of patients after transplantation [25, 33].

**Characteristic features of ulcerative colitis with concomitant primary sclerosing cholangitis**

Previously conducted studies show that when PSC is present, UC seems to demonstrate a characteristic disease phenotype. PSC-IBD may even be a separate disease entity than IBD alone [34, 35]. Patients with PSC were younger at ulcerative colitis diagnosis and had more extensive disease, but disease activity during acute flares was significantly lower, flares had lower incidence, disease activity was decreased – especially in the first 10 years after the diagnosis – and corticosteroids, anti-tumour necrosis factor, and anti-integrin agents were needed less frequently [36, 37].

In PSC-UC patients, in comparison to UC patients, endoscopic disease activity in the right colon is significantly increased, whereas no differences in endoscopic disease activity in the left colon were observed, which may translate to higher extensivity of the disease, as seen in different studies [37, 38]. Another feature related to right colon disease activity in PSC-UC patients is more frequent presence of so-called “backwash ileitis” – defined as endoscopically described presence of patulous ileocaecal valve with increased granularity of the terminal ileal mucosa [39]. Even in clinical remission of UC, when PSC is present, patients present an increased histologic activity in the right colon, and decreased histologic activity in the rectum – a prolonged course of subclinical inflammatory disease activity may explain the predominance of right-sided neoplasia in PSC-UC patients [37, 40]. Another hypothesis, which might explain the greater presence of the right-sided tumours, is a possible build-up of secondary bile acids, which probably exert a carcinogenic influence on the colon [37, 41, 42].

Another difference is a clearly different gut microbiota species pattern in PSC concomitant with IBD and in UC patients, which suggest that PSC-UC and UC alone have a different pathogenetic mechanism. Microbiotic pattern is suggested to be a potential biomarker and even a therapeutic target in these diseases [43]. Case study reports and some evidence suggest that oral vancomycin induces both clinical and mucosal remission in PSC-UC patients, both adults and children. Although promising, this has yet to be determined by longer prospective, randomised controlled trials [44, 45].

In flow cytometry and immunochemistry tests conducted on biopsy samples, in both UC and PSC-UC the numbers of eosinophil granulocytes were increased, but increased eosinophil activation and increased levels of pro-inflammatory cytokines were only observed in UC groups, not in PSC-UC groups [46]. An interesting speculation arose from these results: activated eosinophils may contribute to the protection against cancer development in UC, and this protection is reduced in PSC, which results in higher incidence of neoplasia. It is not yet clear if the changes in lymphocyte populations result from microbiotic changes, from the presence of
secondary biliary acids, or comprise a different element of disease pathophysiology.

**Summary**

The course of ulcerative colitis differs significantly when PSC is present, and the impact of PSC is not yet fully understood. The most notable differences are the presence of more extensive presence of inflammation in colitis but lower activity when PSC is present. One must remember the higher incidence of carcinomas in the PSC-UC group, especially in the right-side part of the colon, which implies the need for frequent colonoscopy screening. More research is being conducted to precisely describe the pathophysiology of the disease, which may yet translate to beneficial diagnostic and therapeutic regimes.

**Conflict of interest**

The authors declare no conflict of interest.

**References**

1. Sairenji T, Collins KL, Evans DV. An update on inflammatory bowel disease. Prim Care 2017; 44: 673-92.
2. Wehkamp J, Götz M, Herrlinger K, et al. Inflammatory bowel disease. Dtsch Arztebl Int 2016; 113: 72-82.
3. Halvik Mi, Moum B, Solberg IC, et al. Work disability in inflammatory bowel disease patients 10 years after disease onset: results from the IBSEN Study. Gut 2013; 62: 368-75.
4. Kingham JG, Kochar N, Gravenor MB. Incidence, clinical patterns, and outcomes of primary sclerosing cholangitis in South Wales, United Kingdom. Gastroenterology 2004; 126: 1929-30.
5. Tanaka A, Mertens JC. Ulcerative colitis with and without primary sclerosing cholangitis: two different diseases? Inflamm Intest Dis 2016; 1: 9-14.
6. Gidwaney NG, Pawa S, Das KM. Pathogenesis and clinical spectrum of primary sclerosing cholangitis. World J Gastroenterol 2017; 23: 2459-69.
7. Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol 2005; 19 (Suppl A): SA-36A.
8. Gajendran M, Loganathan P, Jimenez G, et al. A comprehensive review and update on ulcerative colitis. Dis Mon 2019; 65: 100851.
9. Ungaro R, Mehandru S, Allen PB, et al. Ulcerative colitis. Lancet 2017; 389: 1756-70.
10. Cosnes J, Gower-Rousseau C, Seksik P, et al. Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology 2011; 140: 1785-94.
11. Ungaro R, Colombel JF, Lissoos T, et al. A treat-to-target update in ulcerative colitis: a systematic review. Am J Gastroenterol 2019; 114: 874-83.
12. Reinisch W, Reinink AR, Higgins PDR. Factors associated with poor outcomes in adults with newly diagnosed ulcerative colitis. Clin Gastroenterol Hepatol 2015; 13: 635-42.
13. Halling ML, Kjeldsen J, Knudsen T, et al. Patients with inflammatory bowel disease have increased risk of autoimmune and inflammatory diseases. World J Gastroenterol 2017; 23: 6137-46.
14. Yu YR, Rodríguez JR. Clinical presentation of Crohn’s, ulcerative colitis, and indeterminate colitis: symptoms, extraintestinal manifestations, and disease phenotypes. Semin Pediatr Surg 2017; 26: 349-55.
15. Tripathi K, Feuerstein JD. New developments in ulcerative colitis: latest evidence on management, treatment, and maintenance. Drugs Context 2019; 8: 212572.
16. Chapman R, Fevery J, Kalloo A, et al. Diagnosis and management of primary sclerosing cholangitis. Hepatology 2010; 51: 660-78.
17. Hirschfield GM, Karlsen TH, Lindor KD, et al. Primary sclerosing cholangitis. Lancet 2013; 382: 1587-99.
18. Molodecka NA, Kareemi H, Parab R, et al. Incidence of primary sclerosing cholangitis: a systematic review and meta-analysis. Hepatology 2011; 53: 1590-9.
19. Escorell A, Pares A, Rodes J, et al. Epidemiology of primary sclerosing cholangitis in Spain. Spanish Association for the Study of the Liver. J Hepatol 1994; 21: 787-91.
20. Boonstra K, Weersma RK, van Erpemckl K, et al. Population-based epidemiology, malignancy risk, and outcome of primary sclerosing cholangitis. Hepatology 2013; 58: 2045-55.
21. Karlsen TH, Folsersaa T, Thorburn D, et al. Primary sclerosing cholangitis – a comprehensive review. J Hepatol 2017; 67: 1298-323.
22. Kaplan MM. Medical approaches to primary sclerosing cholangitis. Semin Liver Dis 1991; 11: 56-63.
23. Tischendorf JJ, Hecker H, Krüger M, et al. Characterization, outcome, and prognosis in 273 patients with primary sclerosing cholangitis: a single center study. Am J Gastroenterol 2007; 102: 107-14.
24. Jess T, Simonsen J, Jorgensen KT, et al. Decreasing risk of colorectal cancer in patients with inflammatory bowel disease over 30 years. Gastroenterology 2012; 143: 375-81.
25. Lazaridis KN, LaRusso NF. Primary sclerosing cholangitis. N Engl J Med 2016; 375: 1161-70.
26. Marelli L, Xiouchakakis E, Kalambokis G, et al. Does the severity of primary sclerosing cholangitis influence the clinical course of associated ulcerative colitis? Gut 2011; 60: 1224-8.
27. Broome U, Bergquist A. Primary sclerosing cholangitis, inflammatory bowel disease, and colon cancer. Semin Liver Dis 2006; 26: 31-41.
28. Joo M, Abreu-e-Lima P, Farraye F, et al. Pathologic features of ulcerative colitis in patients with primary sclerosing cholangitis: a case-control study Am J Surg Pathol 2009; 33: 854-62.
29. Befeler AS, Lissoos TW, Schiano TD, et al. Clinical course and management of inflammatory bowel disease after liver transplantation. Transplantation 1998; 65: 393-6.
30. Saarinen S, Olerup O, Broome U. Increased frequency of autoimmune diseases in patients with primary sclerosing cholangitis. Am J Gastroenterol 2000; 95: 3195-9.
31. Jussila A, Virta Li, Puikkala E, et al. Malignancies in patients with inflammatory bowel disease: a nationwide register study in Finland. Scand J Gastroenterol 2013; 48: 1405-13.
32. Khaderi SA, Sussman NL. Screening for malignancy in primary sclerosing cholangitis (PSC). Curr Gastroenterol Rep 2015; 17: 17.
33. Fosby B, Karlseth TH, Melum E. Recurrence and rejection in liver transplantation for primary sclerosing cholangitis. World J Gastroenterol 2012; 18: 1-15.
34. Loftus EV Jr, Harewood GC, Loftus CG, et al. PSC-IBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis. Gut 2005; 54: 91-6.
35. Sano H, Nakazawa T, Ando T, et al. Clinical characteristics of inflammatory bowel disease associated with primary sclerosing cholangitis. J Hepatobiliary Pancreat Sci 2011; 18: 154-61.
36. Cordes E, Laumeyer T, Gerß J, et al. Distinct disease phenotype of ulcerative colitis in patients with coincident primary sclerosing cholangitis: evidence from a large retrospective study with matched cohorts. Dis Colon Rectum 2019; 62: 1494-504.
37. Krugliak Cleveland N, Rubin DT, Hart J, et al. Patients with ulcerative colitis and primary sclerosing cholangitis frequently have subclinical inflammation in the proximal colon. Clin Gastroenterol Hepatol 2018; 16: 68-74.
38. Kumagai J, Taida T, Ogasawara S, et al. Clinical characteristics and outcomes of primary sclerosing cholangitis and ulcerative colitis in Japanese patients. PLoS One 2018; 13: e0209352.
39. Loftus EV, Harewood GC, Loftus CG, et al. PSC-IBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis. Gut 2005; 54: 91-6.
40. Wang R, Leong RW. Primary sclerosing cholangitis as an independent risk factor for colorectal cancer in the context of inflammatory bowel disease: a review of the literature. World J Gastroenterol 2014; 20: 8783-9.
41. Marchesa P, Lashner BA, Lavery IC, et al. The risk of cancer and dysplasia among ulcerative colitis patients with primary sclerosing cholangitis. Am J Gastroenterol 1997; 92: 1285-8.
42. Torres J, de Chambrun GP, Itzkowitz S, et al. Review article: colorectal neoplasia in patients with primary sclerosing cholangitis and inflammatory bowel disease. Aliment Pharmacol Ther 2011; 34: 497-508.
43. Bajer L, Kverka M, Kostovcik M, et al. Distinct gut microbiota profiles in patients with primary sclerosing cholangitis and ulcerative colitis. World J Gastroenterol 2017; 23: 4548-58.
44. De Chambrun GP, Nachury M, Funakoshi N, et al. Oral vancomycin induces sustained deep remission in adult patients with ulcerative colitis and primary sclerosing cholangitis. Eur J Gastroenterol Hepatol 2018; 30: 1247-52.
45. Tan L, Reilly CR, Steward-Harrison LC, et al. Oral vancomycin induces clinical and mucosal remission of colitis in children with primary sclerosing cholangitis – ulcerative colitis. Gut 2019; 68: 1533-5.
46. Lampinen M, Fredricsson A, Vessby J, et al. Downregulated eosinophil activity in ulcerative colitis with concomitant primary sclerosing cholangitis. J Leukocyte Biol 2018; 104: 173-83.

Received: 8.12.2020
Accepted: 30.01.2021